What is the recommended daily dose and dosing frequency of Reglan (metoclopramide) in adults, including oral and intravenous regimens and adjustments for renal impairment?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 13, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Reglan (Metoclopramide) Daily Dose and Frequency

For adults, metoclopramide should be dosed at 10 mg orally or intravenously, administered 20-30 minutes before meals and at bedtime (four times daily), with a maximum daily dose of 40 mg, and doses must be reduced by 50-75% in patients with renal impairment. 1

Standard Adult Dosing

Oral Administration

  • 10 mg four times daily (total 40 mg/day) taken 20-30 minutes before meals and at bedtime 1, 2
  • This regimen has demonstrated efficacy in treating gastroparesis and upper gastrointestinal symptoms 2

Intravenous Administration

  • 10 mg IV administered 20-30 minutes before meals or with analgesics for migraine 1
  • Can be repeated as needed within the maximum daily limit

Maximum Daily Dose

  • 40 mg per day is the standard maximum for adults 2
  • Higher doses increase risk of extrapyramidal symptoms and other adverse effects

Critical Dosing Adjustments for Renal Impairment

Patients with renal failure require substantial dose reductions because metoclopramide clearance is reduced to approximately 30% of normal, and the elimination half-life extends from 4-6 hours to approximately 14 hours. 3, 4

Renal Dosing Guidelines

  • Creatinine clearance correlates directly with metoclopramide plasma clearance 4
  • In renal failure, both renal and non-renal clearance are reduced 4
  • Reduce maintenance doses by 50-75% in patients with significant renal impairment to avoid drug accumulation 4
  • The prolonged half-life (13.9-14.8 hours vs. normal 4-6 hours) necessitates extended dosing intervals 3

Specific Renal Impairment Recommendations

  • Consider dosing 10 mg twice daily or three times daily instead of four times daily in moderate renal impairment
  • In severe renal failure, consider 10 mg once or twice daily 5, 4
  • Monitor closely for extrapyramidal symptoms, as five of six reported cases of metoclopramide-induced parkinsonism occurred in patients with renal failure 5

Important Safety Considerations

Movement Disorders and Neurological Effects

  • Extrapyramidal reactions are dose-dependent and more common with renal impairment 5
  • Symptoms include restlessness, drowsiness, dystonic reactions, and parkinsonism 1, 5
  • Even short-term, low-dose therapy (30-40 mg total over days) can cause severe, long-lasting adverse effects lasting up to 10-13 months 6

Contraindications

  • Pheochromocytoma, seizure disorder, gastrointestinal bleeding, and gastrointestinal obstruction 1

Common Pitfalls to Avoid

  • Failing to reduce doses in elderly patients, who often have unrecognized renal impairment with GFR decreasing approximately 8 mL/min per decade after age 40 7
  • Continuing standard dosing in renal failure patients, which leads to drug accumulation and increased risk of parkinsonism 5, 4
  • Underestimating the duration of adverse effects—neurological symptoms can persist for months even after discontinuation 6

Hemodialysis Considerations

  • Hemodialysis removes relatively small amounts of metoclopramide compared to total body stores 4
  • Compensatory dose increases after dialysis are unnecessary 4
  • Hemodialysis is not effective for metoclopramide overdose 4

Duration of Treatment

  • Metoclopramide should be reserved for short-term use (typically days to weeks, not months) 6
  • Long-term use increases risk of tardive dyskinesia and other movement disorders
  • Re-evaluate need for continued therapy regularly, especially in patients experiencing any neurological symptoms

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

The pharmacokinetics of single doses of metoclopramide in renal failure.

European journal of clinical pharmacology, 1981

Research

Metoclopramide-induced parkinsonism.

Southern medical journal, 1989

Guideline

Clindamycin Dosing in Elderly Patients with Impaired Renal Function

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.